werden die 1., 2., 3., 4., 5., 10., 25., 50., 75., 90., 95., 96., 97., 98. und 99. Perzentilwerte für das Geburtsgewicht, die Länge, den Kopfumfang und das längenbezogene Geburtsgewicht für Mädchen und Knaben angegeben. Gegenüber den bisherigen deutschen Standardwerten von 1992 [1, 2] erfolgt damit eine Präzisierung der Werte, insbesondere im unteren Schwangerschaftsbereich. Folgende Verbesserungen bzw. Veränderungen zu den Werten von 1992 wurden vorgenommen: 1. Durch die hohe Fallzahl konnten die Perzentilwerte schon ab 20 vollendeten Schwangerschaftswochen angegeben werden. 2. Die Berechung der Perzentilwerte erfolgte mithilfe des arithmetischen Mittelwertes (x ) und der Standardabweichung (s) unter der Voraussetzung des Vorliegens einer Normalverteilung der einzelnen Körpermaße. Mit dieser Methode konnten "stark" differenzierte Perzentilwerte berechnet werden. 3. Um den internationalen Anforderungen gerecht zu werden, wurden auch die Werte x -2 s und x + 2 s ausgewiesen. Wir hoffen, dass diese neuen Perzentilwerte nach der Publizierung zur somatischen Klassifikation der Neugeborenen schnelle Anwendung finden und damit die Werte von 1992 ablö- AbstractBased on the perinatal data from 1995 -2000, the 1st, 2nd, 3rd, 4th, 5th, 10th, 25th 50th, 75th, 90th, 95th, 96th, 97th, 98th, 99th percentile values for birth weight, size (length), head circumference, and for length-related birth weight are presented for girls and boys. These data represent more precise percentile values, particularly for the early gestational weeks compared to the currently used German standard data from 1992 [1, 2]. The following updates and modifications were made to the values from 1992: 1. Due to the large number of probands, we were able to establish percentile values already from the 20th completed week of gestation. 2. The calculation of the percentile values was made by means of the arithmetic mean (x ) and the standard deviation (s), provided that the individual somatic measures were normally distributed. With this method, strongly differentiated percentile values could also be calculated. 3. In order to meet international standards, the values x -2 s and x + 2 s are stated as well. We hope that the published percentile values will be applied soon for the somatic classification of newborns and that the data from 1992 will be replaced. For easier use a software programme will be available in the near future. Originalarbeit 956Institutsangaben

Background/Aims: Treatment of children with growth disorders with recombinant human growth hormone is necessary for improved outcomes, including final height. Methods: Adherence data from the Observational Study Saizen®-online, recorded with the easypod™ device collected between October 2009 and May 2011, were analyzed in pediatric patients receiving recombinant human growth hormone treatment for a variety of growth disorders. Results: Data from 75 children (46 boys, 29 girls) with different growth disorders were analyzed over a period of 343 ± 201 (SD) days. Boys and girls showed similar mean ± SD adherence rates of 90.5 ± 3.1% and 92.2 ± 10.7%, respectively. Pubertal children (n = 41) had a significantly lower adherence rate (89.1 ± 13.7%) than prepubertal children (n = 29) (96.5 ± 3.9%; p < 0.005). There were nonsignificant differences in adherence rates according to diagnosis: growth hormone deficiency (n = 48) 91.4 ± 11.0%, small for gestational age (n = 18) 91.1 ± 15.3%, Turner syndrome (n = 6) 86.0 ± 14.5%, and chronic renal failure (n = 3) 99.3 ± 1.0%, although the latter two groups were small. Conclusion: Our data indicate that only a small number of pediatric patients using the easypod device had poor adherence to treatment. Further reliable adherence data are required to identify factors affecting long-term adherence in this population.

Insulin-like growth factor-I (IGF-I) receptors are present in breast cancer cells and may play a role in breast cancer cell growth. We have studied the effect of progestins on IGF-I receptors in T47D human breast cancer cells. T47D cells constitutively express high levels of progesterone receptors and are a model for studying the regulation of cellular functions by progestins. Treatment of T47D cells with either progesterone or the synthetic progestin promegestone (R5020) decreased IGF-I receptor content by approximately 50%, as measured by Scatchard analysis and receptor biosynthesis studies. In contrast to progestins, estradiol, dexamethasone, and dihydrotestosterone did not influence IGF-I receptor content. No effect of R5020 was seen after 12 h of incubation, a near-maximal effect was seen after 24 h, and greatest effects were seen after 72 h. R5020 decreased IGF-I receptor mRNA abundance, indicating that progestins acted at the level of gene expression. However, progestins also increased the secretion of IGF-II, a ligand for the IGF-I receptor. In contrast to IGF-II, T47D cells did not express IGF-I. The addition of exogenous IGF-II to T47D cells down-regulated both IGF-I receptor binding and IGF-I receptor mRNA abundance. This study indicates, therefore, that progestins regulate IGF-I receptors in breast cancer cells and suggests that this regulation occurs via an autocrine pathway involving enhanced IGF-II secretion.

A simple method was developed to isolate low abundance hormone receptor poly(A)+ RNA from cells in tissue culture. Adherent cells in tissue culture plates were directly released with proteinase K and solubilized in SDS. Oligo(dT) cellulose was directly added to the lysate to obtain poly(A)+ RNA. Yields and purity of the poly(A)+ RNA were comparable to other more lengthy methods. IGF-I receptor and insulin receptor mRNA could be detected on Northern blot without any degradation.